Nexus Biopharma, Inc. (NEXS) Financial Statements (2024 and earlier)

Company Profile

Business Address JLABS @ TMCX
HOUSTON, TX 77021-2040
State of Incorp.
Fiscal Year End February 28
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

5/31/2017
Q1
2/28/2017
Q4
11/30/2016
Q3
8/31/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7730262,441   
Cash and cash equivalents7730262,441   
Receivables  8,991    
Prepaid expense1,000     
Total current assets:1,0779,29362,441   
Noncurrent Assets
Property, plant and equipment1,5751,632    
Intangible assets, net (including goodwill)6,8757,3237,770   
Intangible assets, net (excluding goodwill)6,8757,3237,770   
Total noncurrent assets:8,4508,9557,770   
TOTAL ASSETS:9,52718,24870,211   
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:835,514824,261839,97726,99725,94724,897
Accounts payable200,000200,000100,00026,99725,94724,897
Other undisclosed accounts payable and accrued liabilities635,514624,261739,977   
Debt292,500292,500292,500   
Derivative instruments and hedges, liabilities      
Due to related parties87,547  65,72459,47056,970
Other undisclosed current liabilities200,000200,000100,000   
Total current liabilities:1,415,5611,316,7611,232,47792,72185,41781,867
Noncurrent Liabilities
Long-term debt and lease obligation47,77946,11244,445   
Long-term debt, excluding current maturities47,77946,11244,445   
Total noncurrent liabilities:47,77946,11244,445   
Total liabilities:1,463,3401,362,8731,276,92292,72185,41781,867
Equity
Equity, attributable to parent, including:(1,453,813)(1,344,625)(1,206,711)(92,721)(85,417)(81,867)
Common stock64,31064,310643   
Additional paid in capital1,776,3241,776,3241,839,99141,90041,90041,900
Accumulated deficit(3,294,447)(3,185,259)(3,047,345)(198,421)(191,117)(187,567)
Other undisclosed equity, attributable to parent    63,80063,80063,800
Total equity:(1,453,813)(1,344,625)(1,206,711)(92,721)(85,417)(81,867)
TOTAL LIABILITIES AND EQUITY:9,52718,24870,211   

Income Statement (P&L) (USD)

5/31/2017
Q1
2/28/2017
Q4
11/30/2016
Q3
8/31/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
Gross profit:      
Operating expenses(100,308)(128,959)(170,307)(7,304)34,746(6,160)
Operating income (loss):(100,308)(128,959)(170,307)(7,304)34,746(6,160)
Nonoperating expense      
Other undisclosed loss from continuing operations before equity method investments, income taxes     (27,129) 
Income (loss) from continuing operations:(100,308)(128,959)(170,307)(7,304)7,617(6,160)
Income (loss) before gain (loss) on sale of properties:(100,308)(128,959)(170,307)(7,304)7,617(6,160)
Net income (loss):(100,308)(128,959)(170,307)(7,304)7,617(6,160)
Other undisclosed net income (loss) attributable to parent(8,880)(8,956)(9,033) (11,167)3,080
Net loss available to common stockholders, diluted:(109,188)(137,915)(179,340)(7,304)(3,550)(3,080)

Comprehensive Income (USD)

5/31/2017
Q1
2/28/2017
Q4
11/30/2016
Q3
8/31/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
Net income (loss):(100,308)(128,959)(170,307)(7,304)7,617(6,160)
Comprehensive income (loss), net of tax, attributable to parent:(100,308)(128,959)(170,307)(7,304)7,617(6,160)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: